Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹825Cr
Rev Gr TTM
Revenue Growth TTM
12.34%
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | -3.7 | -16.2 | 2.8 | -1.0 | 10.8 | 10.3 | 4.4 | 12.8 | 16.9 | 4.5 | 14.6 | 13.0 |
| 186 | 195 | 216 | 183 | 196 | 194 | 208 | 200 | 234 | 207 | 254 | 238 |
Operating Profit Operating ProfitCr |
| 4.7 | 0.5 | 4.8 | 7.2 | 9.7 | 10.3 | 12.1 | 10.1 | 7.6 | 8.0 | 6.4 | 5.3 |
Other Income Other IncomeCr | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 3 | 2 |
Interest Expense Interest ExpenseCr | 3 | 5 | 5 | 7 | 3 | 4 | 6 | 6 | 9 | 8 | 10 | 9 |
Depreciation DepreciationCr | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 7 | 8 | 8 | 8 |
| 2 | -8 | 3 | 4 | 14 | 15 | 19 | 10 | 4 | 3 | 3 | -2 |
| 1 | -2 | 1 | 2 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 0 |
|
Growth YoY PAT Growth YoY% | -88.7 | -171.9 | -61.8 | -31.3 | 750.4 | 281.5 | 510.7 | 173.6 | -86.0 | -95.5 | -95.0 | -126.9 |
| 0.6 | -3.1 | 1.1 | 1.3 | 4.7 | 5.1 | 6.2 | 3.2 | 0.6 | 0.2 | 0.3 | -0.8 |
| 0.3 | -1.8 | 0.7 | 0.8 | 3.0 | 3.3 | 4.4 | 2.1 | 0.4 | 0.1 | 0.2 | -0.6 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 10.6 | 49.1 | 0.7 | -6.7 | 22.6 | -2.3 | -1.5 | 11.0 | 7.9 |
| 401 | 441 | 640 | 633 | 554 | 776 | 795 | 789 | 835 | 934 |
Operating Profit Operating ProfitCr |
| 12.4 | 12.8 | 15.2 | 16.7 | 21.9 | 10.7 | 6.4 | 5.6 | 10.1 | 6.8 |
Other Income Other IncomeCr | 7 | 0 | -1 | 7 | 2 | 4 | 6 | 7 | 3 | 6 |
Interest Expense Interest ExpenseCr | 5 | 7 | 13 | 12 | 2 | 4 | 13 | 20 | 25 | 36 |
Depreciation DepreciationCr | 14 | 15 | 18 | 19 | 17 | 17 | 19 | 20 | 24 | 31 |
| 44 | 43 | 83 | 103 | 137 | 76 | 27 | 14 | 48 | 7 |
| 16 | 18 | 26 | 17 | 35 | 23 | 8 | 5 | 13 | 6 |
|
| | -10.4 | 128.7 | 50.8 | 18.3 | -47.7 | -63.0 | -53.9 | 277.1 | -97.8 |
| 6.1 | 4.9 | 7.6 | 11.3 | 14.4 | 6.1 | 2.3 | 1.1 | 3.7 | 0.1 |
| 8.3 | 1.9 | 17.7 | 25.6 | 30.3 | 16.1 | 5.9 | 2.7 | 10.2 | 0.2 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 5 | 8 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| 308 | 329 | 375 | 447 | 540 | 588 | 608 | 616 | 646 | 645 |
Current Liabilities Current LiabilitiesCr | 106 | 186 | 233 | 114 | 158 | 186 | 298 | 278 | 375 | 436 |
Non Current Liabilities Non Current LiabilitiesCr | 68 | 49 | 48 | 30 | 29 | 74 | 63 | 84 | 107 | 95 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 258 | 317 | 420 | 363 | 477 | 555 | 639 | 518 | 632 | 690 |
Non Current Assets Non Current AssetsCr | 232 | 256 | 253 | 246 | 268 | 310 | 347 | 477 | 513 | 503 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 16 | -23 | 181 | 17 | -1 | -22 | 142 | -34 |
Investing Cash Flow Investing Cash FlowCr | -31 | -12 | -10 | -35 | -59 | -46 | -99 | -87 |
Financing Cash Flow Financing Cash FlowCr | 15 | 36 | -159 | 16 | 51 | 78 | -48 | 121 |
|
Free Cash Flow Free Cash FlowCr | -15 | -36 | 171 | -18 | -60 | -69 | 43 | -121 |
| 64.2 | -41.0 | 209.9 | 17.0 | -1.5 | -113.0 | 1,557.6 | -99.9 |
CFO To EBITDA CFO To EBITDA% | 24.8 | -20.4 | 142.2 | 11.2 | -0.9 | -41.1 | 302.1 | -36.7 |
| Financial Year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 373 | 732 | 764 | 451 | 1,975 | 2,375 | 1,184 | 1,006 | 928 |
Price To Earnings Price To Earnings | 13.4 | 29.3 | 13.4 | 5.2 | 19.4 | 44.5 | 59.9 | 110.3 | 27.0 |
Price To Sales Price To Sales | 0.8 | 1.4 | 1.0 | 0.6 | 2.8 | 2.7 | 1.4 | 1.2 | 1.0 |
Price To Book Price To Book | 1.2 | 2.2 | 1.9 | 1.0 | 3.5 | 3.9 | 1.9 | 1.6 | 1.4 |
| 8.3 | 13.1 | 8.1 | 3.7 | 13.1 | 27.1 | 25.8 | 25.6 | 13.6 |
Profitability Ratios Profitability Ratios |
| 35.3 | 35.3 | 34.1 | 37.2 | 44.3 | 34.1 | 32.1 | 31.7 | 39.7 |
| 12.4 | 12.8 | 15.2 | 16.7 | 21.9 | 10.7 | 6.4 | 5.6 | 10.1 |
| 6.1 | 4.9 | 7.6 | 11.3 | 14.4 | 6.1 | 2.3 | 1.1 | 3.7 |
| 11.8 | 10.9 | 17.0 | 22.6 | 21.9 | 10.7 | 4.7 | 4.1 | 7.2 |
| 8.9 | 7.4 | 14.6 | 18.6 | 18.3 | 8.8 | 3.2 | 1.4 | 5.2 |
| 5.7 | 4.4 | 8.5 | 14.2 | 13.7 | 6.2 | 2.0 | 0.9 | 3.0 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
#### **Company Overview**
**Oriental Aromatics Ltd (OAL)** is one of India’s oldest and largest integrated manufacturers in the **Flavours & Fragrances (F&F)** and **Aroma Chemicals** industry, with over **seven decades** of experience—dating back to its founding in **1955** by **Mr. Keshavlal V. Bodani**. The company operates across three core verticals:
1. **Camphor & Terpene Chemicals**
2. **Specialty Aroma Ingredients (Aroma Chemicals)**
3. **Flavours & Fragrances**
OAL is among the **few fully integrated global players**, offering **end-to-end capabilities** from concept and R&D to manufacturing of aroma ingredients, fragrances, and flavours. The company is publicly listed and has evolved from a fragrance distributor into a leading global supplier with a vertically integrated model.
---
#### **Business Segments & Key Operations**
##### **1. Camphor & Terpene Chemicals**
- **Core Products**: Synthetic camphor (including pharmaceutical-grade and religious grades), terpineol, pine oils, isobornyl acetate, terpene resins.
- **Applications**: Religious (puja), topical analgesics (pain relief), pharmaceuticals, industrial, and FMCG.
- **Brands**:
- **Saraswati Camphor** (established 1967): Dominant in traditional religious segment.
- **3 Pine Camphor** (including Bhimseni, launched 1994): Targets urban, wellness-focused consumers; market leader in Gujarat & Maharashtra.
- **Manufacturing**:
- **Bareilly Plant (Uttar Pradesh)**:
- India’s first synthetic camphor plant, established in **1964** with **DuPont technology**.
- Production capacity: **7,900 MTPA** of pine-based chemicals and camphor.
- **USFDA and WHO-GMP certified**—one of the few global facilities producing pharmaceutical-grade camphor.
- **Strategic Highlights**:
- **Internalized legacy brands (FY 2024–25)**: OAL now fully owns, manufactures, and markets Saraswati and 3 Pine, which together account for **over 60%** of its powdered camphor production.
- **Domestic dominance**: Strong brand presence across India, especially in North India, Punjab, and Rajasthan.
- **China Import Mitigation**: Domestic synthetic camphor is **more suitable for puja** than imported natural camphor from China, which requires additional processing.
- **Pricing Challenge**: Excess domestic capacity—not Chinese imports—is the primary source of pricing pressure. OAL has adopted **supply discipline** to stabilize pricing.
- **Differentiated Moats**:
- Domestic **spiritual segment** (resilient demand).
- **Global pharmaceutical** use (value-added, regulated market).
##### **2. Specialty Aroma Ingredients (Aroma Chemicals)**
- **Core Offerings**: Musk derivatives (e.g., Astromusk), sandalwood alternatives (e.g., Mysornol), Evermoss AB20018, pinene derivatives, esters, and specialty terpenes.
- **Scale**: Produces **over 150 specialty aroma ingredients** using **28+ advanced chemical processes**.
- **Manufacturing & Expansion**:
- **Vadodara, Gujarat**:
- **6,200 MTPA** of aroma chemicals; **75% exported**.
- Hosts new **multi-product hydrogenation plant** (commissioned July 2024).
- **Mahad, Maharashtra**:
- **250 MTPA** greenfield plant for **Evermoss**, commissioned Nov 2024.
- Fully operational and receiving positive global client feedback.
- **Key Strengths**:
- **Backward Integration**: Supplies its own flavours & fragrances division and global F&F majors like **IFF, Givaudan, and Symrise**.
- **Innovation Focus**: Targets **high-value, low-volume specialty chemicals** with unique IP and process advantages.
- **Sustainability**: Offers biodegradable, green chemistry-based solutions (e.g., Evermoss).
- **Global Leadership**: One of the few **independent, non-aligned** global aroma chemical suppliers.
- **New Product Pipeline**: Targets 33%+ global market share in select molecules (e.g., sandalwood, musk).
##### **3. Flavours & Fragrances (F&F)**
- **Applications**: Personal care (shampoos, soaps), home care (detergents, air fresheners), fine fragrances, incense, candles, beverages, dairy, confectionery, instant foods, oral hygiene.
- **Clients**: Major **FMCG brands** in India, Southeast Asia, Middle East, Africa, and North/South America.
- **Manufacturing**:
- **Ambernath, Maharashtra**:
- **6,000 MTPA** state-of-the-art facility (since 2014) for fragrances and flavours.
- Features integrated R&D, creative formulation, and quality assurance.
- **Growth Drivers**:
- **Premiumization and rural FMCG penetration** in India.
- **Winning Launches**: Achieved **2,534 successful fragrance formulations** in FY 2022–23.
- **New Business Wins**: Secured contracts ahead of festive demand, increased wallet share in home care, personal care, and puja product categories.
- **Custom Innovation**: Develops award-winning, performance-driven scents using in-house perfumers and deep consumer insights.
---
#### **Strategic Positioning & Competitive Advantages**
| **Key Strength** | **Details** |
|------------------|-----------|
| **Vertical Integration** | Full control from R&D to commercial delivery ensures **quality, cost control, and supply security** during global disruptions. |
| **Backward Integration** | Internal production of aroma chemicals reduces raw material volatility exposure. ~60% of camphor is internally consumed. |
| **Global Expansion** | Supplies **2,000+ customers across 30+ countries**, with strong presence in Asia, Middle East, Europe, and Americas. |
| **Sustainability & Innovation** | Uses renewable feedstocks (e.g., alpha-pinene from replanted forests); implements **zero liquid discharge**, biomass boilers, green chemistry. |
| **R&D Capabilities** | Two **DSIR-recognized** centers in **Chandivali (Mumbai)** and **Vadodara**, with **40+ research associates**. Developed **100+ commercial aroma ingredients** using 26–28 chemistries. |
| **New Facilities Driving Growth** | - **Vadodara Hydrogenation Plant** (multi-product, 700 MTPA): Commissioned July 2024, now contributing to profitability. <br> - **Mahad Evermoss Plant** (single-product, 250 MTPA): Operational since Nov 2024. |
| **Strategic Capex Plan** | Investment of **₹3,500–4,000 crores over 3–5 years**, focused on Mahad and Vadodara expansions. Targets **1.7x revenue return** on capital. |
---
#### **Financial & Operational Highlights (FY 2024–25)**
- **Revenue Mix**:
- ~33% from **camphor & terpene chemicals**
- ~33% from **specialty aroma ingredients**
- ~33% from **flavours & fragrances**
- **Performance**:
- **12.9% YoY increase** in production volume
- **4.8% increase** in sales volume
- **11% rise** in operating income
- **10.79% growth** in EBITDA
- **Global Recognition**: Received **P&G’s Global Supplier Excellence Award 2023** (top 80 out of 60,000 suppliers).
---
#### **Challenges & Risk Mitigation**
- **Pricing Pressures**:
- Commodity aroma chemicals face oversupply; countered by **shifting to high-value specialty products**.
- Maintained **disciplined supply** in camphor to avoid price erosion.
- **Raw Material Volatility**:
- **Alpha-pinene** accounts for ~60% of sales—exposure to price swings.
- Mitigated via **diversified sourcing** (no single supplier >10% of requirement) and de-risked procurement.
- **Geopolitical & Trade Risks**:
- Actively **hedges forex** and monitors trade policies; benefits from “**China+1**” diversification trends.
- **Working Capital Intensity**: Extended inventory and debtor days in F&F segment managed via operational efficiency and supply chain optimization.
- **Rising Indian Rupee**: In past, caused margin pressure due to imported raw materials; addressed by **price pass-through mechanisms** and cost leadership.
---
#### **Recent Developments (2024–25)**
- **Internalization of Brands**: Took full control of **Saraswati and 3 Pine**, enhancing margin capture and brand control.
- **Expansion Projects Completed**:
- Hydrogenation plant (Vadodara)
- Evermoss plant (Mahad)
- New 250 MTPA unit at Ambernath (subsidary)
- **R&D & Innovation**:
- 15+ new products in pipeline.
- Evermoss adoption by global customers signals **sustainable product leadership**.
- **Export Growth**: Rising demand for **specialty terpenes and generic chemicals** due to global supply chain diversification.
---
#### **Management & Leadership**
- **Mr. Dharmil A. Bodani**, **Chairman & Managing Director**, leads strategy, innovation, and chemical division. Represents **third-generation leadership** of the Bodani family.
- **Strategic Vision**: Focus on **global leadership in specialty aroma chemicals**, expanding into **high-margin, niche markets**, and building a **sustainable, integrated F&F powerhouse**.